Objective: Emulgels as topical dosage form recently gains an interest represent a combination of gels and emulsions in united form. Metronidazole is an antimicrobial and anti-inflammatory drug, as the first topical therapy approved for rosacea; metronidazole has remained a cornerstone of rosacea management. Methods: Emulgel formulations of metronidazole benzoate were prepared using two types of gelling agents, Carbopol 940 and hydroxypropyl methylcellulose, the influence of type and concentration of them on the release of metronidazole benzoate was investigated. The prepared formulations were evaluated on the basis of pH, spreadability, viscosity, drug content, in vitro release, and compatibility studies. Results: All the prepared emulgels showed acceptable physical properties concerning color, homogeneity, consistency, spreadability, and pH value. Conclusion: The best formulation (F4) prepared using Carbopol 940 as gelling agent showed the highest drug release through 5 h.
Objective: The purpose of this study was to enhance the dissolution pattern of the practically water-insoluble diuretic drug, furosemide through its formulation into liquisolid tablets.Methods: A mathematical model was used to formulate four liquisolid powder systems using polyethylene glycol 400 as a non-volatile water miscible liquid vehicle. The liquid loading factors of the vehicle were used to calculate the optimum quantities of carrier (Avicel PH 102) and coating materials (Aerosil 200) needed to prepare acceptably flowing and compactible powder mixtures and (R) ratio used was 25. The liquisolid tablets were evaluated for weight variation, percent friability, hardness, content uniformity, disintegration time and in vitro drug release profile. Drug and the prepared systems were characterized by fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC) and powder xray diffraction (PXRD) studies. Results:The enhanced dissolution rate due to the increased wetting properties and the large available surface areas for dissolution were obtained in case of the liquisolid tablets. The selected optimal formulation (F2) of 50% drug concentration released 90% of its content during the first 10 min compared to 65% of DCT. FTIR studies revealed that there was no interaction between drug and polymers. DSC and PXRD indicated conversion of crystalline to amorphous form of furosemide. Conclusion:The dissolution rate of furosemide can be enhanced to a great extent by liquisolid technique.
Dissolution of drug is the rate determining step for oral absorption of the poorly water soluble drugs and solubility is the basic requirement for the absorption of the drug from GIT. The development of a soulful dissolution procedure for drug products with lower water solubility has been a provocation to both the pharmaceutical industry and the agencies that regulate them. This study demonstrates the systematic development o f a discriminatory dissolution method for clopidogrel bisulfate, a BCS class II drug exhibiting highly pH-dependent solubility. The method was developed by testing solubility of clopidogrel bisulfate in different concentrations of sodium lauryl sulfate. The results showed 900 ml of 0.1 N HCl and phosphate buffer pH 6.8 containing 1% SLS with a paddle speed of 50 rpm was selected as discriminative dissolution test conditions for clopidogrel bisulfate tablets. In conclusion surfactants and pH changes are very effective ways to increase solubility. The in vitro dissolution must serve as both a quality control tool and a potential surrogate marker of drug bioavailability and bioequivalence.
Objective: The aim of the present work was to formulate and evaluate fast dissolving film containing lornoxicam.Materials and Methods: To prepare the film, hydroxypropyl methylcellulose E5 and polyvinyl alcohol (PVA) were used as film-forming polymers by solvent casting method. Glycerine was used as plasticizer, aspartame, and mannitol as sweetener. All prepared films were evaluated for its weight variation, disintegration time, thickness, drug content, pH, dissolution study, and folding endurance. The drug-excipients compatibility study was done using differential scanning calorimetry (DSC) and Fourier transform infrared (FTIR).Results: Satisfactory results obtained when PVA was used as film-forming polymer, and the drug was dispersed in the polymer solution using poloxamer 407 as a solubilizing agent. Formulation F2 is considered as the optimized formulation as it showed good folding endurance (>300), faster disintegration rate (30 s), and maximum in vitro drug release (87%) within 5 min. DSC and FTIR studies showed no interaction between drug and the polymers.Conclusion: It can be concluded from the study that the fast dissolving film can be prepared for poorly water-soluble drug lornoxicam using PVA as a suitable film-forming polymer.
Increasing requests for modified and personalized pharmaceutics and medical materials makes the implementation of additive manufacturing increased rapidly in recent years. 3D printing has been involved numerous advantages in case of reduction in waste, flexibility in the design, and minimizing the high cost of intended products for bulk production of. Several of 3D printing technologies have been developed to fabricate novel solid dosage forms, including selective laser sintering, binder deposition, stereolithography, inkjet printing, extrusion-based printing, and fused deposition modeling. The selection of 3D printing techniques depends on their compatibility with the printed drug products. This review intent to provide a perspective on the incentives and possible applications of 3D printed pharmaceuticals, besides a practical viewpoint on how 3D printing could be included across the pharmaceutical field.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.